Featured Research

from universities, journals, and other organizations

UCLA Yoga Study Seeks Breast Cancer Survivors

Date:
April 15, 2004
Source:
University Of California - Los Angeles
Summary:
Researchers at UCLA's Jonsson Cancer Center are recruiting volunteers who have completed treatment for breast cancer and are experiencing persistent fatigue to join a study to see if yoga can improve energy, mood and physical functioning.

Researchers at UCLA's Jonsson Cancer Center are recruiting volunteers who have completed treatment for breast cancer and are experiencing persistent fatigue to join a study to see if yoga can improve energy, mood and physical functioning.

"We are interested in yoga because there are some compelling preliminary data that suggest the practice may be associated with improving mood and energy," said Julie Bower, a researcher at UCLA's Jonsson Cancer Center and the Cousins Center for Psychoneuroimmunology at UCLA's Neuropsychiatric Institute and an assistant professor of psychiatry and biobehavioral sciences. "We are collaborating with a local yoga instructor who has worked with breast cancer survivors and is very interested in doing a study to evaluate the potential benefits of yoga for this group."

Today, most women are diagnosed with early-stage breast cancer and most are cured, but many are left with ongoing symptoms. Fatigue is the most common symptom for women with breast cancer both during and after treatment. Research suggests it can endure for years after treatment is completed.

"Our goal is to reduce the side effects of cancer treatment and improve long-term quality of life," Bower said.

The yoga study seeks women between the ages of 45 and 65 who completed treatment between one and five years ago. In addition to the twice-weekly yoga classes, the women will participate in psychiatric interviews, complete questionnaires, and provide blood and saliva samples for immune and hormonal evaluation. The classes will be taught at a yoga studio in West Los Angeles.

Women interested in participating in the study should call Deborah Garet at (310) 267-4423 to determine their eligibility.

###UCLA's Jonsson Comprehensive Cancer Center is composed of more than 240 cancer researchers and clinicians engaged in cancer research, prevention, detection, control and education. The center, one of the nation's largest comprehensive cancer centers, is dedicated to promoting cancer research and applying the results to clinical situations. In 2003 the center was named the best cancer center in the Western United States by U.S. News & World Report, a ranking it has held for four consecutive years. For more information about the center, visit http://www.cancer.mednet.ucla.edu/.


Story Source:

The above story is based on materials provided by University Of California - Los Angeles. Note: Materials may be edited for content and length.


Cite This Page:

University Of California - Los Angeles. "UCLA Yoga Study Seeks Breast Cancer Survivors." ScienceDaily. ScienceDaily, 15 April 2004. <www.sciencedaily.com/releases/2004/04/040412235022.htm>.
University Of California - Los Angeles. (2004, April 15). UCLA Yoga Study Seeks Breast Cancer Survivors. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2004/04/040412235022.htm
University Of California - Los Angeles. "UCLA Yoga Study Seeks Breast Cancer Survivors." ScienceDaily. www.sciencedaily.com/releases/2004/04/040412235022.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins